Discussion
Data demonstrates the widespread use of oral trials across the hospital, with 19.5% (N=118) of patients on the dysphagia caseload being offered oral trials. Neurological diagnosis appears to be a defining factor to whether oral trials are offered. Due to the limited sample size and interaction between variables, it is not possible to determine the extent to which other factors contribute independently to treatment group. However, data begins to reveal clear trends as to when and where oral trials are offered.